Videos

Panelists share their approaches to counseling adult patients with spinal muscular atrophy (SMA) about treatment expectations.

Key opinion leaders share their strategies for discussing potential changes in therapy and transitioning between treatments with patients, emphasizing the importance of reassuring patients that such changes are intended to provide long-term benefits for managing their spinal muscular atrophy.

The chief executive officer and the chief scientific officer at CureDuchenne talked about a recent webinar that discussed the broad FDA approval of a gene therapy for Duchenne muscular dystrophy, highlighting patient choice and the ongoing efforts to improve treatments. [WATCH TIME: 9 minutes]

The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending July 6, 2024. [WATCH TIME: 4 minutes]

The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about making strides in developing minimally invasive tests and imaging ligands for neurodegenerative diseases, such as Parkinson disease. [WATCH TIME: 2 minutes]

The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]

Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.

Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.

An expert on Duchenne muscular dystrophy reviews standard-of-care treatment options and provides clinical insights on adverse effects and safety concerns, particularly with corticosteroids.

The panel reflects on their experiences as practicing clinicians, emphasizing the significance of shared decision-making and actively listening to patients’ preferences regarding management of their MS.

In this episode, Negroski gave insight on the impact of health care-related social determinants of health, their impact on brain structure and aging in MS, and where efforts should be directed towards going forward.

The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.

Key opinion leaders examine the short-term and long-term effects of spasticity on patients' and caregivers' quality of life.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute provided an in-depth explanation of how the Syn-One test is used to help detect patients with Parkinson disease and related disorders. [WATCH TIME: 5 minutes]

Panelists explore critical considerations when choosing a treatment approach for treatment-naïve adult patients with spinal muscular atrophy (SMA), taking into account factors such as disease severity, patient preferences, and potential treatment outcomes.

Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]

The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed how combining advanced therapies with lifestyle modifications can improve outcomes and slow disease progression in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

The director of the OhioHealth ALS Clinic and vice chair of the ALS Association Care Services Committee discussed the upcoming ALS Nexus Conference and how themes of the event align with the direction of clinical care. [WATCH TIME: 3 minutes]

In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.

Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.

Kaleb Yohay, MD, introduces an upcoming Insights series dissecting care for a range of patient ages diagnosed with neurofibromatosis type 1 related plexiform neurofibroma.

The expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.

Multiple sclerosis (MS) specialists discuss their observations regarding variations in MS presentation and progression among patients of Different Races and Ethnicities